A therapeutic aptamer inhibits angiogenesis by specifically targeting the heparin binding domain of VEGF165 -- Lee et al. 102 (52): 18902 Data Supplement - HTML Page - index.htslp -- Proceedings of the National Academy of Sciences

Lee et al. 10.1073/pnas.0509069102.

Supporting Figures

Files in this Data Supplement:

Supporting Figure 6
Supporting Figure 7

Supporting Figure 6

Fig. 6. The fraction of aptamer bound to the HBD is shown as a function of protein concentration with data taken from EMSA. The solid line is the binding curve for a 12 nM K_d. The inset shows an EMSA of the aptamer with increasing concentration of HBD (0.5, 1, 3, 6, 10, 20, 30, 50 and 0 nM HBD).

Supporting Figure 7

Fig. 7. Summary of the sequential and medium range NH-NH and NH-Ha NOE data observed in the 3D NOESY-¹⁵N-HSQC spectra for the HBD-aptamer complex. The thickness of each bar indicates the relative intensity of the NOE.